Blue Jet Healthcare Limited — Q3 FY25 earnings call

Call held 29 Jan 2025

Management summary

Blue Jet Healthcare delivered a record-breaking Q3 FY25, driven by strong execution and the full operationalization of new capacities in Unit 2. The company reported significant growth across revenue, EBITDA, and PAT, with pharmaceutical intermediates being a key driver. Management expressed confidence in sustained growth, supported by a robust order book, ongoing R&D investments, and strategic capacity expansions, including an upward revision in annual EBITDA margin expectations.

Highlights

  • Q3 FY25 Revenue reached INR3,184 million, up 53% QoQ and 91% YoY.

  • Q3 FY25 PAT surged to INR990 million, marking a 70% QoQ and 208% YoY increase, the highest ever quarterly profit.

  • Q3 FY25 EBITDA stood at INR1,240 million, growing 79% QoQ and 127% YoY, with an EBITDA margin of 39%.

  • For 9M FY25, revenue was INR6,895 million (up 31% YoY), EBITDA INR2,378 million (up 35% YoY), and PAT INR1,951 million (up 57% YoY).

  • Pharmaceutical intermediates segment turnover for 9M FY25 grew 352% YoY to INR2,663 million.

  • R&D investment of INR40 crores for equipment is planned for FY26, with operating expenses expected to double from INR5-6 crores (FY25) to INR10-12 crores (FY26).

  • New capacity additions in Unit 2 for cardiovascular and contrast media intermediates were fully operationalized, with optimal utilization for NCE expected by H1 2026.

  • Annual EBITDA margin guidance was revised upwards to 'in excess of 35%, 37%' from the previous 30-33% range.

Key financials

2 periods

Q3 FY25

  • Revenue
    3,184 Mn
    YoY +91% QoQ +53%
  • EBITDA
    1,240 Mn
    YoY +127% QoQ +79%
  • PAT
    990 Mn
    YoY +208% QoQ +70%
  • EBITDA Margin
    39%

9M FY25

  • Revenue
    6,895 Mn
    YoY +31%
  • EBITDA
    2,378 Mn
    YoY +35%
  • PAT
    1,951 Mn
    YoY +57%
  • EBITDA Margin
    34.5%
  • PAT Margin
    28.3%

What they filed

Q1 FY27: revenue down 17.5%, net profit down 14.3% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue208 318 340 355 165 −21%192 −40%235 −31%293 −17%
EBITDA69 124 140 121 55 −20%47 −62%71 −49%98 −19%
Net profit58 99 110 91 52 −10%40 −60%64 −42%78 −14%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

Share of Turnover
6,729 Mn Total
  • Contrast Media (9M FY25) 3,028 Mn 45.0%
  • Pharmaceutical Intermediates (9M FY25) 2,663 Mn 39.6%
  • Saccharin (9M FY25) 1,038 Mn 15.4%

Guidance & targets

Capacity

  • Optimal capacity utilization for new NCE molecule Capacity · H1 2026 · High confidence Optimal utilization levels
    commercial production has commenced, and we expect to optimize capacity utilizations by H1 2026.

    — Shiven Arora

  • Unit 3 Mahad Operational Capacity · H2 FY26 · High confidence Go live
    We expect to go live now in H2 FY '26.

    — VK Singh

Capex

  • R&D Capex (equipment) Capex · FY26 · High confidence INR40 crores
    The INR40 crores is going to be more on equipment. It's more of a capex, okay?

    — Ganesh Karuppannan

  • Additional Capex for existing projects Capex · Near term · Medium confidence INR1,500 million
    we hope to spend an additional INR1,500 million on the existing projects, mostly in Mahad.

    — Ganesh Karuppannan

Operating Expense

  • R&D Operating Expense Operating Expense · FY26 · Medium confidence INR10-12 crores

    Previously INR5-6 crores → INR10-12 crores

    the operating expense would be in the range of -- expectation would be around INR10 crores to INR12 crores. The current number is somewhere close to INR5 crores to INR6 crores.

    — Ganesh Karuppannan

Margin

  • Annual EBITDA Margin Margin · Annual basis · Medium confidence in excess of 35%, 37%

    Previously 30%-33% → in excess of 35%, 37%

    When you do that in that fashion, we should expect an EBITDA in excess of 35%, 37%.

    — Ganesh Karuppannan

Risks & concerns

  • Patent expiry for the key cardiovascular product

    medium

    Initial patent expiry was 2026, but extensions in US (2031) and Europe (2032) provide protection from generic competition.

    Analyst acknowledged

  • Capacity constraints for the growing demand of the cardiovascular product

    low

    Management stated there is no constraining factor and they can double capacity through debottlenecking without adding more reactors due to flexible plant design.

    Analyst downplayed

  • Saccharin being replaced by sucralose and competition from China

    low

    Management asserted saccharin is a stable product not being replaced, and Blue Jet operates in a niche FMCG/pharma segment with strong customer stickiness despite Chinese competition.

    Analyst downplayed

Areas of evasion (3)

  • Specific names of partners under CDA
  • Exact pipeline numbers under CDA
  • Precise order book value or future growth rate numbers beyond general encouragement

Q&A highlights

3 direct
Sustainability and patent expiry of the key cardiovascular pharmaceutical intermediate product. Direct
So, the initial patent expiry was in 2026, but then there was a patent term extension given granted for the molecule. So, in the U.S., I think it is 2031. In Europe, you get an additional marketing exclusivity. So, I think it will go to 2032. So, I think till that point of time, we are protected from generic competition in this molecule.

This question clarified the long-term patent protection for a significant growth driver, reassuring investors about the product's sustainability against generic competition.

Asked by Sanjesh Jain

Breakdown of the INR40 crores R&D investment into capital expenditure and operating expenses, and its comparison to current spend. Direct
The INR40 crores is going to be more on equipment. It's more of a capex, okay? It is -- the operating expense would be in the range of -- expectation would be around INR10 crores to INR12 crores. The current number is somewhere close to INR5 crores to INR6 crores.

This provided crucial detail on the nature and scale of R&D investment, distinguishing between infrastructure and operational costs, and indicating a significant increase in R&D focus.

Asked by Kunal Dhamesha

Sustainability of the strong Q3 volume run rate for pharmaceutical intermediates and the potential for operational leverage. Direct
Based on the current order book and customer forecast, short to medium term, it is pretty encouraging for us, and we should be in a position to sustain similar margins or growth.

This addressed concerns about the Q3 performance being a one-off, providing reassurance on the continued strong growth in the pharmaceutical intermediates segment based on current demand visibility.

Asked by Darshan Engineer

3 min read 6 chapters

Detailed narrative

Q3 FY25 Record Performance & 9M Overview

Blue Jet Healthcare reported a record-breaking Q3 FY25, with revenue reaching INR3,184 million, marking a 53% quarter-over-quarter and 91% year-over-year growth. Profit After Tax (PAT) surged to INR990 million, up 70% QoQ and 208% YoY, representing the highest ever quarterly profit. EBITDA for the quarter stood at INR1,240 million, growing 79% QoQ and 127% YoY, with an EBITDA margin of 39%. For the nine months ended December 2024, revenue from operations was INR6,895 million (up 31% YoY), EBITDA was INR2,378 million (up 35% YoY), and PAT was INR1,951 million (up 57% YoY).

Capacity Expansion and Operationalization Drive Growth

The strong Q3 performance was primarily driven by new capacity additions in Unit 2, which were fully operationalized during the quarter. This included 120 KL capacity in Phase 1 for cardiovascular intermediates and an additional 37 KL capacity in Phase 2 for contrast media intermediates. Commercial production for the NCE molecule has commenced, with optimal utilization expected by H1 2026. Unit 3 at Mahad, focused on backward integration for contrast media, is now expected to go live in H2 FY26, following a redesigned process for higher quality and safety.

Strategic R&D Investments & Future Pipeline Focus

Recognizing innovation's critical role, Blue Jet Healthcare plans to invest INR40 crores in R&D equipment in FY26, alongside an increase in R&D operating expenses from INR5-6 crores in FY25 to INR10-12 crores in FY26. These investments will focus on developing advanced intermediates, expanding the contrast media portfolio, and enhancing CDMO capabilities for high-value projects, including amino acid derivatives for GLP-1 products. The company is building new chemistry platforms and labs for quick turnaround of RFPs for advanced intermediates.

Segmental Performance & Outlook

For the nine months, the pharmaceutical intermediates category reported a significant turnover of INR2,663 million, up 352% year-over-year, driven by optimized new capacity. The contrast media segment saw a turnover of INR3,028 million, a degrowth of 17% due to past customer offtake issues, but new product launches are expected to sustain growth. The saccharin category grew 10% to INR1,038 million, with management noting its stability and niche market position, not seeing replacement by sucralose.

EBITDA Margin Expansion & Operational Leverage

The company's Q3 EBITDA margin reached 39%, significantly impacting operational leverage. For the 9-month period, the EBITDA margin was 34.5%. Management indicated that with sustained turnover levels in coming quarters, they expect to benefit further from operational leverage, improving the annual EBITDA margin to 'in excess of 35%, 37%', an upward revision from the previous 30-33% range. This improvement is attributed to sales growth, expansion in EBITDA margin, and a change in depreciation method.

Capital Expenditure & Working Capital Management

Working capital for the nine months increased by INR1,200 million, primarily due to higher inventory for pharmaceutical intermediates, which will be optimized over time. The company capitalized production capacities amounting to INR1,000 million during the 9-month period. Additionally, they spent INR620 million and anticipate spending an additional INR1,500 million on existing projects, mainly in Mahad, alongside the INR400 million R&D investment slated for FY26.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls